publication date: Jul. 26, 2019

Conversation with The Cancer Letter

IASLC: The Lung Ambition Alliance will amplify initiatives in lung cancer on a global scale

Dave Mesko2 copy

Dave Mesko

Chief executive officer,

International Association
for the Study of Lung Cancer

 

Giorgio Scagliotti2 copy

Giorgio V. Scagliotti

President, IASLC

Head, Department of Oncology,

Professor of medical oncology,

University of Torino, Italy 

 

The founding partners of the Lung Ambition Alliance launched the group July 8 with the primary objective of doubling five-year survival rates for patients with lung cancer—up to 40%.

The alliance, which seeks to include additional partners, was founded by the International Association for the Study of Lung Cancer, the Global Lung Cancer Coalition, Guardant Health, and AstraZeneca.

“It’s important to note that the alliance represents a broad array of talent and skill sets,” said IASLC CEO Dave Mesko. “We have the IASLC, which specializes in research and education, Guardant Health, which specializes in the diagnostic space, GLCC, which represents 37 international patient advocacy organizations and of … Continue reading IASLC: The Lung Ambition Alliance will amplify initiatives in lung cancer on a global scale

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.